Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Edgewise Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:09 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056713
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Purchases of marketable securities | (110,152) | (122,180) |
| Sales of marketable securities | 3,966 | 15,000 |
| Maturities of marketable securities | 108,879 | 151,122 |
| Purchases of property and equipment | (260) | (44) |
| Net cash provided by investing activities | 2,433 | 43,898 |
| Cash flows from financing activities | ||
| Exercise of stock options | 12,173 | 2,261 |
| Payment of deferred offering costs | — | (38) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Edgewise Therapeutics, Inc.'s capex?
- Edgewise Therapeutics, Inc. (EWTX) reported capex of $260K in Q1 2026.
- How has Edgewise Therapeutics, Inc.'s capex changed year-over-year?
- Edgewise Therapeutics, Inc.'s capex increased by 490.9% year-over-year, from $44K to $260K.
- What is the long-term trend for Edgewise Therapeutics, Inc.'s capex?
- Over 4 years (2021 to 2025), Edgewise Therapeutics, Inc.'s capex has grown at a -21.3% compound annual growth rate (CAGR), from $668K to $256K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Edgewise Therapeutics, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude